(UroToday.com) Androgen deprivation therapy in prostate cancer is an effective treatment for a certain period of time and does improve prognosis. However, there is concern over long term side effects, including cardiovascular events. It has been shown that long-term androgen deprivation therapy increases the cardiovascular event rate. 20 to 30% of prostate cancer patients have pre-existing cardiovascular disease, and their prognosis has been shown to be worse as they may have a greater increase in cardiovascular risk when started therapy with androgen deprivation therapy.